190 related articles for article (PubMed ID: 27609641)
1. Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma.
Cazzamalli S; Dal Corso A; Neri D
Mol Cancer Ther; 2016 Dec; 15(12):2926-2935. PubMed ID: 27609641
[TBL] [Abstract][Full Text] [Related]
2. A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
Krall N; Pretto F; Mattarella M; Müller C; Neri D
J Nucl Med; 2016 Jun; 57(6):943-9. PubMed ID: 26912427
[TBL] [Abstract][Full Text] [Related]
3. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.
Cazzamalli S; Corso AD; Neri D
J Control Release; 2017 Jan; 246():39-45. PubMed ID: 27890855
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Cazzamalli S; Ziffels B; Widmayer F; Murer P; Pellegrini G; Pretto F; Wulhfard S; Neri D
Clin Cancer Res; 2018 Aug; 24(15):3656-3667. PubMed ID: 29691298
[No Abstract] [Full Text] [Related]
5. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
Alsaab HO; Sau S; Alzhrani RM; Cheriyan VT; Polin LA; Vaishampayan U; Rishi AK; Iyer AK
Biomaterials; 2018 Nov; 183():280-294. PubMed ID: 30179778
[TBL] [Abstract][Full Text] [Related]
6. Targeting carbonic anhydrase IX with small organic ligands.
Wichert M; Krall N
Curr Opin Chem Biol; 2015 Jun; 26():48-54. PubMed ID: 25721398
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the Pharmacokinetics of a Radioligand Targeting Carbonic Anhydrase-IX with Albumin-Binding Moieties.
Iikuni S; Okada Y; Shimizu Y; Watanabe H; Ono M
Mol Pharm; 2021 Mar; 18(3):966-975. PubMed ID: 33472371
[TBL] [Abstract][Full Text] [Related]
8. Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
Thomas LJ; Vitale L; O'Neill T; Dolnick RY; Wallace PK; Minderman H; Gergel LE; Forsberg EM; Boyer JM; Storey JR; Pilsmaker CD; Hammond RA; Widger J; Sundarapandiyan K; Crocker A; Marsh HC; Keler T
Mol Cancer Ther; 2016 Dec; 15(12):2946-2954. PubMed ID: 27671527
[TBL] [Abstract][Full Text] [Related]
9. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
[TBL] [Abstract][Full Text] [Related]
10. Noninternalizing targeted cytotoxics for cancer therapy.
Casi G; Neri D
Mol Pharm; 2015 Jun; 12(6):1880-4. PubMed ID: 25738312
[TBL] [Abstract][Full Text] [Related]
11. Acetazolamide-based [
More KN; Lee JY; Kim DY; Cho NC; Pyo A; Yun M; Kim HS; Kim H; Ko K; Park JH; Chang DJ
Bioorg Med Chem Lett; 2018 Mar; 28(5):915-921. PubMed ID: 29422388
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.
Petrul HM; Schatz CA; Kopitz CC; Adnane L; McCabe TJ; Trail P; Ha S; Chang YS; Voznesensky A; Ranges G; Tamburini PP
Mol Cancer Ther; 2012 Feb; 11(2):340-9. PubMed ID: 22147747
[TBL] [Abstract][Full Text] [Related]
13. Copper-Free 'Click' Chemistry-Based Synthesis and Characterization of Carbonic Anhydrase-IX Anchored Albumin-Paclitaxel Nanoparticles for Targeting Tumor Hypoxia.
Tatiparti K; Sau S; Gawde KA; Iyer AK
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29534020
[TBL] [Abstract][Full Text] [Related]
14. Site-Specific Chemical Modification of a Cytokine Mimic for Small Molecule-Based Tumor Targeting.
Mortensen M; Bertolini M; Mock J; Scheuermann J; Oehler S
Bioconjug Chem; 2023 Aug; 34(8):1374-1379. PubMed ID: 37462264
[TBL] [Abstract][Full Text] [Related]
15. Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.
de Goeij BE; Vink T; Ten Napel H; Breij EC; Satijn D; Wubbolts R; Miao D; Parren PW
Mol Cancer Ther; 2016 Nov; 15(11):2688-2697. PubMed ID: 27559142
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Nonpeptidic Ligand Conjugates for the Treatment of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers.
Lv PC; Roy J; Putt KS; Low PS
Mol Cancer Ther; 2017 Mar; 16(3):453-460. PubMed ID: 27980101
[TBL] [Abstract][Full Text] [Related]
17. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
18. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors.
Krall N; Pretto F; Decurtins W; Bernardes GJ; Supuran CT; Neri D
Angew Chem Int Ed Engl; 2014 Apr; 53(16):4231-5. PubMed ID: 24623670
[TBL] [Abstract][Full Text] [Related]
19. Tumor Targeting with Small Molecule-Drug Conjugates (SMDCs) - Can They be Better than ADCs?
Altmann KH
Chimia (Aarau); 2018 Mar; 72(3):154-155. PubMed ID: 29631670
[No Abstract] [Full Text] [Related]
20. Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines.
Mokhtari RB; Kumar S; Islam SS; Yazdanpanah M; Adeli K; Cutz E; Yeger H
BMC Cancer; 2013 Aug; 13():378. PubMed ID: 23927827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
